Evaluate immunogenicity, reactogenicity and safety of 2 doses of GSK [GlaxoSmithKline] Biologicals' oral live attenuated HRV [human rotavirus] vaccine (RIX4414 at 10exp6.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh.
Latest Information Update: 07 Sep 2023
At a glance
- Drugs RIX 4414 (Primary) ; Poliovirus vaccine live oral
- Indications Rotavirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GSK
- 25 Feb 2009 Results were published in Vaccine in Feb 2009.
- 09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 Oct 2008.
- 09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 Oct 2008.